SCHEMBL1436244

SCHEMBL1436244

O=C(O)c1cccc(S(=O)(=O)F)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 3/20 0.57
PRSS1 P07477 3/20 0.57
PRSS2 P07478 3/20 0.57
PRSS3 P35030 3/20 0.57
CA1 P00915 2/20 0.57
CA2 P00918 2/20 0.57
MAPT P10636 1/20 0.56
IL1RN P18510 1/20 0.56
CYP2C19 P33261 1/20 0.54
AKR1C3 P42330 4/20 0.53
ALDH1A1 P00352 2/20 0.53
AKR1C1 Q04828 1/20 0.53
LMNA P02545 1/20 0.53
MEP1B Q16820 1/20 0.51
CA12 O43570 1/20 0.50
CA6 P23280 1/20 0.50
CA9 Q16790 1/20 0.50
APEX1 P27695 1/20 0.50
KDM4E B2RXH2 1/20 0.50
TSHR P16473 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30901134 1.00 F2 (0.57) F2PRSS1PRSS2PRSS3CA1
SCHEMBL31439621 0.98 F2 (0.56) F2PRSS1PRSS2PRSS3CA1
SCHEMBL2405304 0.83 F2 (0.61) F2PRSS1PRSS2PRSS3CA1
SCHEMBL29964265 0.83 F2 (0.61) F2PRSS1PRSS2PRSS3CA1
SCHEMBL30901132 0.82 CA2 (0.46) F2PRSS1PRSS2PRSS3CA1
SCHEMBL30901133 0.82 CA2 (0.46) F2PRSS1PRSS2PRSS3CA1
SCHEMBL6517138 0.82 CA2 (0.46) F2PRSS1PRSS2PRSS3CA1
SCHEMBL4093243 0.82 ALDH1A1 (0.55) CA1CA2ALDH1A1LMNACA12
SCHEMBL31196958 0.82 GAA (0.55) F2PRSS1PRSS2PRSS3CA1
SCHEMBL9674696 0.82 F2 (0.59) F2PRSS1PRSS2PRSS3CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2866029-A1 METHOD FOR PREPARING SAMPLE CONTAINING PANCREATIC JUICE COMPONENT, AND KIT FOR STORING BIOLOGICAL SAMPLE CONTAINING PANCREATIC JUICE COMPONENT AT ROOM TEMPERATURE Olympus Corporation (JP) 2015-04-29 EP claimed
CN-104395749-A Method for preparing sample containing pancreatic juice component, and kit for storing biological sample containing pancreatic juice component at room temperature OLYMPUS CORP 2015-03-04 CN claimed
EP-2757151-A1 METHOD FOR INHIBITING PROTEASE IN BIOLOGICAL SAMPLE CONTAINING PANCREATIC JUICE COMPONENT Olympus Corporation (JP) 2014-07-23 EP claimed
US-20140186869-A1 METHOD FOR INHIBITING PROTEASE IN BIOLOGICAL SAMPLE CONTAINING PANCREATIC JUICE COMPONENTS OLYMPUS CORPORATION (JP) 2014-07-03 US claimed
US-12630566-B2 KRas G12D inhibitors Mirati Therapeutics, Inc. (US) 2026-05-19 US disclosed
US-20260042806-A1 NOVEL PORE MONOMERS AND PORES OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2026-02-12 US disclosed
EP-4665733-A1 AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 Bristol-Myers Squibb Company (US) 2025-12-24 EP disclosed
US-12390424-B2 Sulfur (VI) fluoride compounds and methods for the preparation thereof THE SCRIPPS RESEARCH INSTITUTE (US) 2025-08-19 US disclosed
WO-2025136134-A1 DIMETHYLBIPHENYL COVALENT PD-L1/PD-1 INTERACTION INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAID INHIBITOR AND THE USE THEREOF Uniwersytet Jagielloński (PL) 2025-06-26 WO disclosed
EP-4569330-A1 NOVEL PORE MONOMERS AND PORES Oxford Nanopore Technologies PLC (GB) 2025-06-18 EP disclosed
US-20240309020-A1 KRAS G12D INHIBITORS ARRAY BIOPHARMA INC. 2024-09-19 US disclosed
WO-2024173323-A1 AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 BRISTOL-MYERS SQUIBB COMPANY (US) 2024-08-22 WO disclosed
US-20100075848-A1 Laser Imaging DATALASE LTD. (GB) 2010-03-25 US disclosed
EP-1704057-A1 LASER IMAGING Sherwood Technology LTD. (GB) 2006-09-27 EP disclosed
WO-2005068207-A1 LASER IMAGING DATALASE LTD. (GB) 2005-07-28 WO disclosed
US-4978607-A CONTAINING GELATIN, MODIFIED WITH MONOFUNCTIONAL ACID DERIVATIVE, AND HARDENER, A CARBAMOYL PYRIDINIUM SALT; WITHOUT RETICULATED GRAIN AGFA-GEVAERT AKTIENGESSELLSCHAFT (DE) 1990-12-18 US disclosed
US-4407939-A GELATIN MODIFIED WITH SUCCINIC, PHTHALIC OR TRIMELLITIC ANHYDRIDE POSITIONED BETWEEN FUJI PHOTO FILM CO., LTD. (JP) 1983-10-04 US disclosed
US-4051303-A RECORDING SHEET FUJI PHOTO FILM CO., LTD. (JA) 1977-09-27 US disclosed
US-4021245-A GELATION DERIVATIVE, SILICIC ACID ANHYDRIDE FUJI PHOTO FILM CO., LTD. (JA) 1977-05-03 US disclosed
US-3944502-A Process for preparing microcapsules containing hydrophobic oil drops FUJI PHOTO FILM CO., LTD. (JA) 1976-03-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12390424-B2 Sulfur (VI) fluoride compounds and methods for the preparation thereof GRB2, SCTR, OGFR F2 929/4885PRSS1 2129/4885PRSS2 1293/4885
US-12630566-B2 KRas G12D inhibitors KRAS, NRAS, HRAS F2 3533/4885PRSS1 1338/4885PRSS2 2677/4885
US-20260042806-A1 NOVEL PORE MONOMERS AND PORES SCNN1G, CACNG3, ASIC3 F2 1607/4885PRSS1 1357/4885PRSS2 2116/4885
US-20240309020-A1 KRAS G12D INHIBITORS KRAS, NRAS, HRAS F2 2972/4885PRSS1 1587/4885PRSS2 2240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.